Currently Enrolling

This is a clinical trial of investigational drug ViaDisc NP allograft for replacement of nucleus tissue in patients with symptomatic degenerated discs and resulting low back pain. ViaDisc NP consists of micronized nucleus pulposus tissue from a cadaveric disc tissue. Possible benefits of this clinical study include improvement in pain and function in individuals with discogenic pain. This study involves a total of 5 visits at our site over the course of 6 months, and includes a stipend for each visit.

See if you’re eligible: ViaDisc NP Pre-Screening

Learn more about this study »

This is a Phase 2b/3a clinical trial study of investigational drug JointStem in participants experiencing moderate to severe pain due to osteoarthritis of the knee. JointStem is an autologous adipose derived cellular injection to the affected knee. The possible benefits include increased mobility in the knee and reduction in pain symptoms. This study involves a total of 8 visits at our site over the course of 1 year, and includes a stipend for each visit.

See if you’re eligible: JointStem Knee OA Pre-Screening

Learn more about this study »

This is a Phase 3 clinical trial study of investigational drug TG-C in participants experiencing chronic pain from knee osteoarthritis. TG-C is to be administered by a single intra-articular injection to the damaged joint area. Possible benefits include delayed progression of knee OA, longer knee joint preservation, and improved quality of life. The study will include 11 follow-up visits over the course of 24 months, and includes a stipend for each visit.

See if you’re eligible: TissueGene Knee OA Pre-Screening

Learn more about this study »